• Plus Therapeutics entered a collaboration with Genomic Testing Cooperative to add next-generation sequencing to the CNSide cerebrospinal fluid assay platform.
• Deal aims to enable DNA and RNA profiling across hundreds of biomarkers from a single CSF sample, expanding CNSide beyond tumor cell enumeration.
• Move aligns CNSide with updated NCCN CNS Cancers Guidelines that recognize CSF tumor cells alongside tumor-derived DNA in CSF analysis.
• CNSide test received AMA PLA code 0640U effective July 1, 2026; the CNSide CLIA lab is enrolled with Medicare.
• Targets leptomeningeal metastases, estimated at 5%-10% of metastatic solid tumors, representing more than 100,000 U.S. patients annually.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Plus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607160730PRIMZONEFULLFEED9763164) on July 16, 2026, and is solely responsible for the information contained therein.